TipRanks
Go Ultimate55% OFF

Magda Marquet Insider Profile

4 Followers

Magda Marquet, Director at First Tracks Biotherapeutics Inc, holds 15.96K shares in First Tracks Biotherapeutics Inc (Ticker: TRAX), holds 72.34K shares in Immix Biopharma (Ticker: IMMX), holds 9.93K shares in AnaptysBio (Ticker: ANAB).

Magda Marquet's Trading History

TRAX
First Tracks Biotherapeutics Inc
Jun 17, 2026DirectorUninformative Buy107.82K$719.48K
IMMX
Immix Biopharma
May 29, 2026DirectorUninformative Buy―$555.59K
ANAB
AnaptysBio
Jan 16, 2026DirectorUninformative Buy287.21K$479.42K
ARCT
Arcturus Therapeutics
Jun 18, 2024DirectorUninformative Buy97.06K$309.65K
RNAZ
TransCode Therapeutics
―Director――
PFNX
Pfenex
――――

You May Also Like

Magda Marquet insider profile FAQ

What is the percentage of profitable transactions made by Magda Marquet?
The percentage of profitable transactions made by Magda Marquet is 33%.
What is the average return per transaction made by Magda Marquet?
The average return per transaction made by Magda Marquet is 48.50%.
What stocks does Magda Marquet hold?
Magda Marquet holds: TRAX, ARCT, PFNX, ANAB, RNAZ, IMMX stocks.
What was Magda Marquet’s latest transaction?
Magda Marquet’s latest transaction was an Uninformative Buy of $107.82K.
What was Magda Marquet's most profitable transaction?
Magda Marquet’s most profitable transaction was an Informative Buy of ARCT stock on September 17, 2019. The return on the trade was 316.90%.
What is Magda Marquet's role in First Tracks Biotherapeutics Inc?
Magda Marquet's role in First Tracks Biotherapeutics Inc is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.

TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.